{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pechlivani N"],"funding":["British Heart Foundation","Diabetes UK","Wellcome Trust"],"pagination":["89-100"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11742610"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["<h4>Abstract</h4>Hypofibrinolysis is a documented abnormality in conditions with high risk of vascular occlusion. A key inhibitor of fibrinolysis is α2-antiplasmin (α2AP), and we hypothesize that the Affimer technology, comprising small conformational proteins with 2 9-amino-acid variable regions, can be used to modulate α2AP activity and facilitate fibrinolysis. Using a phage display system, a library of Affimers was screened against α2AP. A total of 28 α2AP-specific Affimers were isolated, of which 1, termed Affimer A11, inhibited protein function and enhanced fibrinolysis. Affimer A11 displayed a monomeric form and consistently reduced the lysis time of clots made from plasma samples of individuals with type 2 diabetes mellitus (n = 15; from 150.8 ± 100.9 to 109.8 ± 104.8 minutes) and t"],"journal":["Blood advances"],"pubmed_title":["Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis."],"pmcid":["PMC11742610"],"funding_grant_id":["FS/IBSRF/22/25130","14/0005006"],"pubmed_authors":["Tomlinson DC","Almutairi M","Tiede C","Ponnambalam S","Alsayejh B","Kietsiriroje N","Duval C","Simmons K","Gaule T","Ajjan RA","Pechlivani N","Phoenix F","Ariens RAS"],"additional_accession":[]},"is_claimable":false,"name":"Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis.","description":"<h4>Abstract</h4>Hypofibrinolysis is a documented abnormality in conditions with high risk of vascular occlusion. A key inhibitor of fibrinolysis is α2-antiplasmin (α2AP), and we hypothesize that the Affimer technology, comprising small conformational proteins with 2 9-amino-acid variable regions, can be used to modulate α2AP activity and facilitate fibrinolysis. Using a phage display system, a library of Affimers was screened against α2AP. A total of 28 α2AP-specific Affimers were isolated, of which 1, termed Affimer A11, inhibited protein function and enhanced fibrinolysis. Affimer A11 displayed a monomeric form and consistently reduced the lysis time of clots made from plasma samples of individuals with type 2 diabetes mellitus (n = 15; from 150.8 ± 100.9 to 109.8 ± 104.8 minutes) and t","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-02T20:11:34.592Z","creation":"2025-04-04T14:05:56.518Z"},"accession":"S-EPMC11742610","cross_references":{"pubmed":["39504559"],"doi":["10.1182/bloodadvances.2024014235"]}}